-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $40 at Guggenheim
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Raised to $7.50 at H.C. Wainwright
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
-
-
-
-
-
-
-
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease o
-
-
-
-
15,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

